NEOMED Announces a New Collaboration with Johnson & Johnson Innovation to Advance Drug Discovery and Development Programs

NEOMED Announces a New Collaboration with Johnson & Johnson Innovation to 
Advance Drug Discovery and Development Programs 
MONTREAL, Dec. 10, 2013 /CNW Telbec/ - NEOMED, a leading drug discovery and 
development public-private partnership in Canada, today announced a new 
collaboration with Johnson & Johnson Innovation, and its affiliate Janssen 
Inc. Canada, to accelerate the transition of university and biotechnology 
company early-stage research into potential treatments. 
Through this collaboration, teams of experienced technical experts at both the 
Johnson & Johnson Innovation Center in Boston, Massachusetts and NEOMED will 
work together to identify and advance medically important projects. These 
projects will come from NEOMED's network of partnered academic institutions 
and biotechnology companies, as well as from Canadian, US and international 
drug discovery groups. 
"NEOMED welcomes the opportunity to work with the pharmaceutical researchers 
at Johnson & Johnson Innovation in this innovative business model," said Dr. 
Max Fehlmann, President and CEO of NEOMED and the NEOMED Institute. "Johnson & 
Johnson Innovation has been a pioneer in large Pharma external research and 
the reinvention of the drug discovery enterprise. We look forward to their 
valuable contribution in support of our mission of helping academia to 
efficiently translate early innovations into high value drug candidates." 
Johnson & Johnson Innovation is the third global pharmaceutical company 
collaborator to join NEOMED since its founding in late 2012. The other global 
pharmaceutical company partners are AstraZeneca and Pfizer. 
AboutNEOMED and the NEOMED Institute
NEOMED was set up one year ago to support the transition of promising drug 
discovery technologies and therapeutic approaches emerging from academic and 
biotechnology companies, and to bring these emerging therapeutics to IND or 
Phase II human proof-of-concept, which are stages when the drug candidates 
become most attractive to the biopharmaceutical companies. NEOMED is jointly 
funded by AstraZeneca, Pfizer and the Ministère des Finances et de 
l'Économie du Québec. 
NEOMED's sole focus is drug discovery, and preclinical and early clinical drug 
development. It has a team of scientists with industry-level expertise and 
capabilities ranging from medicinal chemistry, drug target validation studies 
through animal pharmacology, toxicology and clinical trials design and 
implementation. 
NEOMED is established within the NEOMED Institute, a state-of-the-art R&D 
facility in the Montreal Technoparc. The Institute acts as an open-access drug 
discovery hub hosting drug discovery and development research companies, 
providing a unique environment to foster innovation, collaboration and 
creativity.
For more information, please visit: www.neomed.ca
 

SOURCE  NEOMED 
Mounia Azzi, PhD Director, Scientific Affairs NEOMED (514) 909-7714 
mazzi@neomed.ca  
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/December2013/10/c9177.html 
CO: NEOMED
ST: Quebec
NI: BTC VNT  
-0- Dec/10/2013 13:00 GMT